Search

Your search keyword '"Laslop, A"' showing total 1,052 results
Start Over Author "Laslop, A"
1,052 results on '"Laslop, A"'

4. Evidence-Based Guideline for the management of osteoporosis in men

Author

Fuggle, Nicholas R., Beaudart, Charlotte, Bruyère, Olivier, Abrahamsen, Bo, Al-Daghri, Nasser, Burlet, Nansa, Chandran, Manju, Rosa, Mario M., Cortet, Bernard, Demonceau, Céline, Dere, Willard, Halbout, Philippe, Hiligsmann, Mickaël, Kanis, John A., Kaufman, Jean-Marc, Kurth, Andreas, Lamy, Olivier, Laslop, Andrea, Maggi, Stefania, Matijevic, Radmila, McCloskey, Eugene, Mobasheri, Ali, Prieto Yerro, Maria C., Radermecker, Régis P., Sabico, Shaun, Al-Saleh, Yousef, Silverman, Stuart, Veronese, Nicola, Rizzoli, René, Cooper, Cyrus, Reginster, Jean-Yves, and Harvey, Nicholas C.

Published
2024
Full Text
View/download PDF

6. Real-world evidence: new opportunities for osteoporosis research. Recommendations from a Working Group from the European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (ESCEO)

Author

Moon, Rebecca J., Reginster, Jean-Yves, Al-Daghri, Nasser M., Thiyagarajan, Jotheeswaran A., Beaudart, Charlotte, Bruyère, Olivier, Burlet, Nansa, Chandran, Manju, da Silva, Mario Coelho, Conaghan, Philip G., Dere, Willard H., Diez-Perez, Adolfo, Hadji, Peyman, Halbout, Philippe, Hiligsmann, Mickaël, Kanis, John A., McCloskey, Eugene V., Ormarsdottir, Sif, Prieto-Alhambra, Daniel, Radermecker, Régis P., Rizzoli, René, Al-Saleh, Yousef, Silverman, Stuart L., Simon, Lee S., Thomasius, Friederike, van Staa, Tjeerd, Laslop, Andrea, Cooper, Cyrus, and Harvey, Nicholas C.

Published
2023
Full Text
View/download PDF

7. Measuring health-related quality of life in sarcopenia: summary of the SarQoL psychometric properties

Author

Beaudart, Charlotte, Reginster, Jean-Yves, Amuthavalli Thiyagarajan, Jotheeswaran, Bautmans, Ivan, Bauer, Jürgen, Burlet, Nansa, Cesari, Matteo, Cherubini, Antonio, Cooper, Cyrus, Cruz-Jentoft, Alfonso J., Dawson-Hughes, Bess, Fielding, Roger A., Harvey, Nicholas C., Landi, Francesco, Laslop, Andrea, Maggi, Stefania, Montero-Errasquin, Beatriz, Concepción, Prieto Yerro María, Rolland, Yves, Rizzoli, René, Visser, Marjolein, and Bruyère, Olivier

Published
2023
Full Text
View/download PDF

8. Structural basis for context-specific inhibition of translation by oxazolidinone antibiotics

Author

Tsai, Kaitlyn, Stojković, Vanja, Lee, D John, Young, Iris D, Szal, Teresa, Klepacki, Dorota, Vázquez-Laslop, Nora, Mankin, Alexander S, Fraser, James S, and Fujimori, Danica Galonić

Subjects
Biochemistry and Cell Biology, Biological Sciences, Infectious Diseases, Antimicrobial Resistance, 5.1 Pharmaceuticals, Development of treatments and therapeutic interventions, Infection, Alanine, Anti-Bacterial Agents, Binding Sites, Cryoelectron Microscopy, Linezolid, Models, Molecular, Oxazolidinones, Peptidyl Transferases, Protein Biosynthesis, RNA, Ribosomal, RNA, Transfer, Ribosomes, Chemical Sciences, Medical and Health Sciences, Biophysics, Developmental Biology, Biological sciences, Biomedical and clinical sciences, Chemical sciences
Abstract

The antibiotic linezolid, the first clinically approved member of the oxazolidinone class, inhibits translation of bacterial ribosomes by binding to the peptidyl transferase center. Recent work has demonstrated that linezolid does not inhibit peptide bond formation at all sequences but rather acts in a context-specific manner, namely when alanine occupies the penultimate position of the nascent chain. However, the molecular basis for context-specificity has not been elucidated. Here we show that the second-generation oxazolidinone radezolid also induces stalling with a penultimate alanine, and we determine high-resolution cryo-EM structures of linezolid- and radezolid-stalled ribosome complexes to explain their mechanism of action. These structures reveal that the alanine side chain fits within a small hydrophobic crevice created by oxazolidinone, resulting in improved ribosome binding. Modification of the ribosome by the antibiotic resistance enzyme Cfr disrupts stalling due to repositioning of the modified nucleotide. Together, our findings provide molecular understanding for the context-specificity of oxazolidinones.

Published
2022

11. Inclusion of functional measures and frailty in the development and evaluation of medicines for older adults

Author

Denkinger, Michael, Knol, Wilma, Cherubini, Antonio, Simonds, Anita, Lionis, Christos, Lacombe, Denis, Petelos, Elena, McCarthy, Mary, Ouvrard, Patrick, Van Kerrebroeck, Philip, Szymański, Piotr, Cupelli, Amelia, Laslop, Andrea, Koch, Armin, Sepodes, Bruno, Torre, Carla, Rönnemaa, Elina, Bałkowiec-Iskra, Ewa, Herdeiro, Maria Teresa, Rosa, Mário Miguel, Trauffler, Martine, Mirošević Skvrce, Nikica, Mayrhofer, Sabine, Berntgen, Michael, Silva, Ivana, and Cerreta, Francesca

Published
2023
Full Text
View/download PDF

13. Structural basis for context-specific inhibition of translation by oxazolidinone antibiotics

Author

Tsai, Kaitlyn, Stojković, Vanja, Lee, D John, Young, Iris D, Szal, Teresa, Vazquez-Laslop, Nora, Mankin, Alexander S, Fraser, James S, and Fujimori, Danica Galonić

Subjects
Biochemistry and Cell Biology, Biological Sciences, Antimicrobial Resistance, Development of treatments and therapeutic interventions, 5.1 Pharmaceuticals, Infection
Abstract

ABSTRACT The antibiotic linezolid, the first clinically approved member of the oxazolidinone class, inhibits translation of bacterial ribosomes by binding to the peptidyl transferase center. Recent work has demonstrated that linezolid does not inhibit peptide bond formation at all sequences but rather acts in a context-specific manner, namely when alanine occupies the penultimate position of the nascent chain. In this study, we determined that the second-generation oxazolidinone radezolid also induces stalling with alanine at the penultimate position. However, the molecular basis for context-specificity of these inhibitors has not been elucidated. In this study, we determined high-resolution cryo-EM structures of both linezolid and radezolid-stalled ribosome complexes. These structures reveal that the alanine side chain fits within a small hydrophobic crevice created by oxazolidinone, resulting in improved ribosome binding. Modification of the ribosome by the antibiotic resistance enzyme Cfr disrupts stalling by forcing the antibiotic to adopt a conformation that narrows the hydrophobic alanine pocket. Together, the structural and biochemical findings presented in this work provide molecular understanding of context-specific inhibition of translation by clinically important oxazolidinone antibiotics.

Published
2021

14. Biochemical Markers of Musculoskeletal Health and Aging to be Assessed in Clinical Trials of Drugs Aiming at the Treatment of Sarcopenia: Consensus Paper from an Expert Group Meeting Organized by the European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (ESCEO) and the Centre Académique de Recherche et d'Expérimentation en Santé (CARES SPRL), Under the Auspices of the World Health Organization Collaborating Center for the Epidemiology of Musculoskeletal Conditions and Aging

Author

Ladang, Aurélie, Beaudart, Charlotte, Reginster, Jean-Yves, Al-Daghri, Nasser, Bruyère, Olivier, Burlet, Nansa, Cesari, Matteo, Cherubini, Antonio, da Silva, Mario Coelho, Cooper, Cyrus, Cruz-Jentoft, Alfonso J., Landi, Francesco, Laslop, Andrea, Maggi, Stefania, Mobasheri, Ali, Ormarsdottir, Sif, Radermecker, Régis, Visser, Marjolein, Yerro, Maria Concepcion Prieto, Rizzoli, René, and Cavalier, Etienne

Published
2023
Full Text
View/download PDF

16. Role of vitamin D supplementation in the management of musculoskeletal diseases: update from an European Society of Clinical and Economical Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (ESCEO) working group

Author

Chevalley, Thierry, Brandi, Maria Luisa, Cashman, Kevin D., Cavalier, Etienne, Harvey, Nicholas C., Maggi, Stefania, Cooper, Cyrus, Al-Daghri, Nasser, Bock, Oliver, Bruyère, Olivier, Rosa, Mario Miguel, Cortet, Bernard, Cruz-Jentoft, Alfonso J., Cherubini, Antonio, Dawson-Hughes, Bess, Fielding, Roger, Fuggle, Nicholas, Halbout, Philippe, Kanis, John A., Kaufman, Jean-Marc, Lamy, Olivier, Laslop, Andrea, Yerro, Maria Concepción Prieto, Radermecker, Régis, Thiyagarajan, Jotheeswaran Amuthavalli, Thomas, Thierry, Veronese, Nicola, de Wit, Marten, Reginster, Jean-Yves, and Rizzoli, René

Published
2022
Full Text
View/download PDF

17. Multimodal Multidisciplinary Management of Patients with Moderate to Severe Pain in Knee Osteoarthritis: A Need to Meet Patient Expectations

Author

Veronese, Nicola, Cooper, Cyrus, Bruyère, Olivier, Al-Daghri, Nasser M., Branco, Jaime, Cavalier, Etienne, Cheleschi, Sara, da Silva Rosa, Mario Coelho, Conaghan, Philip G., Dennison, Elaine M., de Wit, Maarten, Fioravanti, Antonella, Fuggle, Nicholas R., Haugen, Ida K., Herrero-Beaumont, Gabriel, Honvo, Germain, Laslop, Andrea, Matijevic, Radmila, Migliore, Alberto, Mobasheri, Ali, Pelletier, Jean-Pierre, Prieto Yerro, María Concepción, Radermecker, Régis Pierre, Rannou, François, Rizzoli, René, and Reginster, Jean-Yves

Published
2022
Full Text
View/download PDF

18. Management of hand osteoarthritis: from an US evidence-based medicine guideline to a European patient-centric approach

Author

Fuggle, Nicholas, Bere, Nathalie, Bruyère, Olivier, Rosa, Mario Manuel, Prieto Yerro, María Concepción, Dennison, Elaine, Dincer, Fitnat, Gabay, Cem, Haugen, Ida K., Herrero-Beaumont, Gabriel, Hiligsmann, Mickaël, Hochberg, Marc C., Laslop, Andrea, Matijevic, Radmila, Maheu, Emmanuel, Migliore, Alberto, Pelletier, Jean-Pierre, Radermecker, Régis Pierre, Rannou, François, Uebelhart, Brigitte, Uebelhart, Daniel, Veronese, Nicola, Vlaskovska, Mila, Rizzoli, René, Mobasheri, Ali, Cooper, Cyrus, and Reginster, Jean-Yves

Published
2022
Full Text
View/download PDF

20. Correction: Biochemical Markers of Musculoskeletal Health and Aging to be Assessed in Clinical Trials of Drugs Aiming at the Treatment of Sarcopenia: Consensus Paper from an Expert Group Meeting Organized by the European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (ESCEO) and the Centre Académique de Recherche et d'Expérimentation en Santé (CARES SPRL), Under the Auspices of the World Health Organization Collaborating Center for the Epidemiology of Musculoskeletal Conditions and Aging

Author

Ladang, Aurélie, Beaudart, Charlotte, Reginster, Jean-Yves, Al-Daghri, Nasser, Bruyère, Olivier, Burlet, Nansa, Cesari, Matteo, Cherubini, Antonio, da Silva, Mario Coelho, Cooper, Cyrus, Cruz-Jentoft, Alfonso J., Landi, Francesco, Laslop, Andrea, Maggi, Stefania, Mobasheri, Ali, Ormarsdottir, Sif, Radermecker, Régis, Visser, Marjolein, Yerro, Maria Concepcion Prieto, Rizzoli, René, and Cavalier, Etienne

Published
2023
Full Text
View/download PDF

21. Formas verbales aspectuales en enunciados directivos (siglos XII‒XXI)

Author

María Eugenia Vázquez Laslop

Subjects
Romanic languages, PC1-5498
Abstract

Aspectual verb forms in directive utterances (12th‒21th centuries) It is described the use of Spanish aspectual verbal constructions in directive utterances between the 12th and 21st centuries. It is argued that, in addition to their aspectual values, these constructions fulfil some pragmatic functions in formal registers, especially some politeness verbal strategies in legal and administrative discourse, as well as the expression of instructions in procedural discourse. Some other illocutionary functions are found in dialogue. These non aspectual functions are documented from classical Spanish to the 20th century.

Published
2022
Full Text
View/download PDF

23. Interdisciplinary management of FGF23-related phosphate wasting syndromes: a Consensus Statement on the evaluation, diagnosis and care of patients with X-linked hypophosphataemia

Author

Trombetti, Andrea, Al-Daghri, Nasser, Brandi, Maria Luisa, Cannata-Andía, Jorge B., Cavalier, Etienne, Chandran, Manju, Chaussain, Catherine, Cipullo, Lucia, Cooper, Cyrus, Haffner, Dieter, Harvengt, Pol, Harvey, Nicholas C., Javaid, Muhammad Kassim, Jiwa, Famida, Kanis, John A., Laslop, Andrea, Laurent, Michaël R., Linglart, Agnès, Marques, Andréa, Mindler, Gabriel T., Minisola, Salvatore, Yerro, María Concepción Prieto, Rosa, Mario Miguel, Seefried, Lothar, Vlaskovska, Mila, Zanchetta, María Belén, and Rizzoli, René

Published
2022
Full Text
View/download PDF

25. Paenilamicins from the honey bee pathogen Paenibacillus larvae are context-specific translocation inhibitors of protein synthesis

Author

Koller, Timm O., primary, Berger, Max J., additional, Morici, Martino, additional, Paternoga, Helge, additional, Bulatov, Timur, additional, Di Stasi, Adriana, additional, Dang, Tam, additional, Mainz, Andi, additional, Raulf, Karoline, additional, Crowe-McAuliffe, Caillan, additional, Scocchi, Marco, additional, Mardirossian, Mario, additional, Beckert, Bertrand, additional, Vázquez-Laslop, Nora, additional, Mankin, Alexander, additional, Süssmuth, Roderich D., additional, and Wilson, Daniel N., additional

Published
2024
Full Text
View/download PDF

27. Structural basis for the tryptophan sensitivity of TnaC-mediated ribosome stalling

Author

Anne-Xander van der Stel, Emily R. Gordon, Arnab Sengupta, Allyson K. Martínez, Dorota Klepacki, Thomas N. Perry, Alba Herrero del Valle, Nora Vázquez-Laslop, Matthew S. Sachs, Luis R. Cruz-Vera, and C. Axel Innis

Subjects
Science
Abstract

Bacteria adjust the expression of some of their metabolic enzymes through metabolite-sensing ribosome nascent chain complexes. Here the authors present a cryo-EM structure of an E. coli ribosome stalled during translation of the TnaC leader peptide and propose a model for L-Trp dependent ribosome stalling where L-Trp competes with release factor 2 for binding to the TnaC-ribosome complex.

Published
2021
Full Text
View/download PDF

28. Structural and mechanistic basis for translation inhibition by macrolide and ketolide antibiotics

Author

Bertrand Beckert, Elodie C. Leroy, Shanmugapriya Sothiselvam, Lars V. Bock, Maxim S. Svetlov, Michael Graf, Stefan Arenz, Maha Abdelshahid, Britta Seip, Helmut Grubmüller, Alexander S. Mankin, C. Axel Innis, Nora Vázquez-Laslop, and Daniel N. Wilson

Subjects
Science
Abstract

Macrolides and ketolides antibiotics selectively interfere with the translation of a specific subset of proteins. Here the authors show how the macrolide erythromycin and the ketolide telithromycin interplay with the nascent polypeptide chain to arrest translation.

Published
2021
Full Text
View/download PDF

29. Discovery of Unannotated Small Open Reading Frames in Streptococcus pneumoniae D39 Involved in Quorum Sensing and Virulence Using Ribosome Profiling

Author

Irina Laczkovich, Kyle Mangano, Xinhao Shao, Adam J. Hockenberry, Yu Gao, Alexander Mankin, Nora Vázquez-Laslop, and Michael J. Federle

Subjects
ribosome profiling, Streptococcus pneumoniae D39, small proteins, small open reading frames, virulence, quorum sensing, Microbiology, QR1-502
Abstract

ABSTRACT Streptococcus pneumoniae, an opportunistic human pathogen, is the leading cause of community-acquired pneumonia and an agent of otitis media, septicemia, and meningitis. Although genomic and transcriptomic studies of S. pneumoniae have provided detailed perspectives on gene content and expression programs, they have lacked information pertaining to the translational landscape, particularly at a resolution that identifies commonly overlooked small open reading frames (sORFs), whose importance is increasingly realized in metabolism, regulation, and virulence. To identify protein-coding sORFs in S. pneumoniae, antibiotic-enhanced ribosome profiling was conducted. Using translation inhibitors, 114 novel sORFs were detected, and the expression of a subset of them was experimentally validated. Two loci associated with virulence and quorum sensing were examined in deeper detail. One such sORF, rio3, overlaps with the noncoding RNA srf-02 that was previously implicated in pathogenesis. Targeted mutagenesis parsing rio3 from srf-02 revealed that rio3 is responsible for the fitness defect seen in a murine nasopharyngeal colonization model. Additionally, two novel sORFs located adjacent to the quorum sensing receptor rgg1518 were found to impact regulatory activity. Our findings emphasize the importance of sORFs present in the genomes of pathogenic bacteria and underscore the utility of ribosome profiling for identifying the bacterial translatome. IMPORTANCE This work employed pleuromutilin-assisted ribosome profiling using retapamulin (Ribo-RET) to identify genome-wide translation start sites in the human pathogen Streptococcus pneumoniae. We identified 114 unannotated intergenic small open reading frames (sORFs). The described procedures and data sets provide a model for microbiologists seeking to explore the translational landscape of bacteria. The biological roles of four sORF examples are characterized: two control the regulation of a cell-cell communication (quorum sensing) system, one contributes to the ability of S. pneumoniae to colonize the upper respiratory tract of mice, and a fourth governs the translation of PrfB, a protein enabling ribosome release at stop codons. We propose that Ribo-RET is a valuable approach to identifying unstudied microproteins and difficult-to-find pheromone genes used by Gram-positive organisms, whose genomes are replete with pheromone receptors.

Published
2022
Full Text
View/download PDF

30. Context-specific action of macrolide antibiotics on the eukaryotic ribosome

Author

Maxim S. Svetlov, Timm O. Koller, Sezen Meydan, Vaishnavi Shankar, Dorota Klepacki, Norbert Polacek, Nicholas R. Guydosh, Nora Vázquez-Laslop, Daniel N. Wilson, and Alexander S. Mankin

Subjects
Science
Abstract

Macrolide antibiotics inhibit bacterial translation in a context-specific manner, arresting ribosomes at defined sites within mRNAs and selectively inhibiting synthesis of only a subset of cellular proteins. Here the authors provide a structural basis for the context-specific activity of macrolides on the eukaryotic ribosome.

Published
2021
Full Text
View/download PDF

31. Medicines for an aging population: The EMA perspective and policies.

Author

Cerreta, Francesca, Iskra, Ewa Balkowiec, Cupelli, Amelia, Sepodes, Bruno, Rönnemaa, Elina, Rosa, Mário Miguel, Mayrhofer, Sabine, Trauffler, Martine, Torre, Carla, Berntgen, Michael, Vucic, Katarina, Bahri, Priya, Koch, Armin, Herdeiro, Maria Teresa, Mirošević Skvrce, Nikica, Pallos, Julia, and Laslop, Andrea

Subjects
DATABASES, MEDICAL information storage & retrieval systems, GERIATRICS, FRAIL elderly, INVESTIGATIONAL drugs, CLINICAL trials, HEALTH, MARKETING, INFORMATION resources, DRUG approval, AGING, COMMUNICATION, DRUG development
Abstract

The European Medicines Agency adopted their Geriatric Medicines Strategy more than a decade ago. The strategy aims at elucidating the evidence basis for marketing authorization of new medicines which will be used in the older population, and at ensuring the appropriate communication of findings to the patient and healthcare provider. During the past decade new tools and data sources have emerged to support the strategy goals, and their use should be considered. Possible concrete actions are presented to improve the design of clinical trials, the data collection both pre‐ and post‐approval, the assessment of the findings, and the communication to assist informed prescription and safe medicine taking. Implementation and prioritization of these actions should be done from the perspective of addressing the needs of patients while maximizing efficient use of resources, with the aim of integrating geriatric aspects into routine medicines development and assessment. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

33. Update on the ESCEO recommendation for the conduct of clinical trials for drugs aiming at the treatment of sarcopenia in older adults

Author

Reginster, Jean-Yves, Beaudart, Charlotte, Al-Daghri, Nasser, Avouac, Bernard, Bauer, Jürgen, Bere, Nathalie, Bruyère, Olivier, Cerreta, Francesca, Cesari, Matteo, Rosa, Mario Miguel, Cooper, Cyrus, Cruz Jentoft, Alfonso J., Dennison, Elaine, Geerinck, Anton, Gielen, Evelien, Landi, Francesco, Laslop, Andrea, Maggi, Stefania, Prieto Yerro, María Concepción, Rizzoli, René, Sundseth, Hildrun, Sieber, Cornel, Trombetti, Andrea, Vellas, Bruno, Veronese, Nicola, Visser, Marjolein, Vlaskovska, Mila, and Fielding, Roger A.

Published
2021
Full Text
View/download PDF

35. Ribosome engineering reveals the importance of 5S rRNA autonomy for ribosome assembly

Author

Shijie Huang, Nikolay A. Aleksashin, Anna B. Loveland, Dorota Klepacki, Kaspar Reier, Amira Kefi, Teresa Szal, Jaanus Remme, Luc Jaeger, Nora Vázquez-Laslop, Andrei A. Korostelev, and Alexander S. Mankin

Subjects
Science
Abstract

Ribosomes of all organisms have retained 5S rRNA as an autonomous rRNA species. Here the authors engineer a bacterial strain with ribosomes that do not have free 5S rRNA, and carry structural analyses that suggest the evolutionary preservation of 5S rRNA as an independent molecule is based on its role in the dynamic process of ribosome biogenesis.

Published
2020
Full Text
View/download PDF

36. A fully orthogonal system for protein synthesis in bacterial cells

Author

Nikolay A. Aleksashin, Teresa Szal, Anne E. d’Aquino, Michael C. Jewett, Nora Vázquez-Laslop, and Alexander S. Mankin

Subjects
Science
Abstract

Ribosome engineering is an emerging powerful approach for synthetic protein synthesis. Here the authors invert the Ribo-T system, using the engineered ribosome to translate the proteome while the native ribosome translates specific mRNA.

Published
2020
Full Text
View/download PDF

44. Apresentação

Author

Leandra Cristina Oliveira, Izete Lehmkuhl Coelho, and María Eugenia Vázquez Laslop

Subjects
Philology. Linguistics, P1-1091
Abstract

Este número Formas e fórmulas de tratamento do mundo hispânico, luso e brasileiro sistematiza resultados de alguns trabalhos apresentados no III Congresso Formas e fórmulas de tratamento do mundo hispánico e luso-brasileiro (IIICFFT), realizado na Universidade Federal de Santa Catarina, entre 7 e 9 de maio de 2018. Os artigos, em geral, estão relacionados à análise histórica e diacrônica do tratamento e à reconstrução diacrônica a partir da sincronia variacionista, duas das temáticas propostas no Congresso. Os resultados apresentados buscam discutir aspectos sócio-históricos, geográficos e estilísticos envolvidos no uso das fórmulas e formas de tratamento, bem como algumas correlações dessas formas com clíticos e formas verbais imperativas com foco especialmente no português.

Published
2019
Full Text
View/download PDF

45. Assembly and functionality of the ribosome with tethered subunits

Author

Nikolay A. Aleksashin, Margus Leppik, Adam J. Hockenberry, Dorota Klepacki, Nora Vázquez-Laslop, Michael C. Jewett, Jaanus Remme, and Alexander S. Mankin

Subjects
Science
Abstract

The tethered ribosome system Ribo-T supports cell proliferation though at a reduced rate. Here the authors show this is due to slower ribosome assembly instead of reduced functionality.

Published
2019
Full Text
View/download PDF

46. Determinants, consequences and potential solutions to poor adherence to anti-osteoporosis treatment: results of an expert group meeting organized by the European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (ESCEO) and the International Osteoporosis Foundation (IOF)

Author

Hiligsmann, M., Cornelissen, D., Vrijens, B., Abrahamsen, B., Al-Daghri, N., Biver, E., Brandi, M.L., Bruyère, O., Burlet, N., Cooper, C., Cortet, B., Dennison, E., Diez-Perez, A., Gasparik, A., Grosso, A., Hadji, P., Halbout, P., Kanis, J.A., Kaufman, J.M., Laslop, A., Maggi, S., Rizzoli, R., Thomas, T., Tuzun, S., Vlaskovska, M., and Reginster, J.Y.

Published
2019
Full Text
View/download PDF

47. Algorithm for the Use of Biochemical Markers of Bone Turnover in the Diagnosis, Assessment and Follow-Up of Treatment for Osteoporosis

Author

Lorentzon, Mattias, Branco, Jaime, Brandi, Maria Luisa, Bruyère, Olivier, Chapurlat, Roland, Cooper, Cyrus, Cortet, Bernard, Diez-Perez, Adolfo, Ferrari, Serge, Gasparik, Andrea, Herrmann, Markus, Jorgensen, Niklas Rye, Kanis, John, Kaufman, Jean-Marc, Laslop, Andrea, Locquet, Médéa, Matijevic, Radmila, McCloskey, Eugene, Minisola, Salvatore, Pikner, Richard, Reginster, Jean-Yves, Rizzoli, René, Szulc, Pawel, Vlaskovska, Mila, and Cavalier, Etienne

Published
2019
Full Text
View/download PDF

48. Is There Enough Evidence for Osteosarcopenic Obesity as a Distinct Entity? A Critical Literature Review

Author

Bauer, Jürgen M., Cruz-Jentoft, Alfonso J., Fielding, Roger A., Kanis, John A., Reginster, Jean-Yves, Bruyère, Olivier, Cesari, Matteo, Chapurlat, Roland, Al-Daghri, Nasser, Dennison, Elaine, Kaufman, Jean-Marc, Landi, Francesco, Laslop, Andrea, Locquet, Médéa, Maggi, Stefania, McCloskey, Eugene, Perna, Simone, Rizzoli, René, Rolland, Yves, Rondanelli, Mariangela, Szulc, Pawel, Vellas, Bruno, Vlaskovska, Mila, and Cooper, Cyrus

Published
2019
Full Text
View/download PDF

49. Practical guidance for engaging patients in health research, treatment guidelines and regulatory processes: results of an expert group meeting organized by the World Health Organization (WHO) and the European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (ESCEO)

Author

de Wit, Maarten, Cooper, Cyrus, Tugwell, Peter, Bere, Nathalie, Kirwan, John, Conaghan, Philip G., Roberts, Charlotte, Aujoulat, Isabelle, Al-Daghri, Nasser, Araujo de Carvalho, Islene, Barker, Mary, Bedlington, Nicola, Brandi, Maria Luisa, Bruyère, Olivier, Burlet, Nansa, Halbout, Philippe, Hiligsmann, Mickaël, Jiwa, Famida, Kanis, John A., Laslop, Andrea, Lawrence, Wendy, Pinto, Daniel, Prieto Yerro, Concepción, Rabenda, Véronique, Rizzoli, René, Scholte-Voshaar, Marieke, Vlaskovska, Mila, and Reginster, Jean-Yves

Published
2019
Full Text
View/download PDF

50. Biochemical Markers of Musculoskeletal Health and Aging to be Assessed in Clinical Trials of Drugs Aiming at the Treatment of Sarcopenia

Author

Aurélie Ladang, Charlotte Beaudart, Jean-Yves Reginster, Nasser Al-Daghri, Olivier Bruyère, Nansa Burlet, Matteo Cesari, Antonio Cherubini, Mario Coelho da Silva, Cyrus Cooper, Alfonso J. Cruz-Jentoft, Francesco Landi, Andrea Laslop, Stefania Maggi, Ali Mobasheri, Sif Ormarsdottir, Régis Radermecker, Marjolein Visser, Maria Concepcion Prieto Yerro, René Rizzoli, and Etienne Cavalier

Subjects
Clinical trial, Sarcopenia, Endocrinology, SDG 3 - Good Health and Well-being, Endocrinology, Diabetes and Metabolism, Biochemical markers, Orthopedics and Sports Medicine, Pharmacological drugs, Recommendations, Biomarkers
Abstract

In clinical trials, biochemical markers provide useful information on the drug’s mode of action, therapeutic response and side effect monitoring and can act as surrogate endpoints. In pharmacological intervention development for sarcopenia management, there is an urgent need to identify biomarkers to measure in clinical trials and that could be used in the future in clinical practice. The objective of the current consensus paper is to provide a clear list of biochemical markers of musculoskeletal health and aging that can be recommended to be measured in Phase II and Phase III clinical trials evaluating new chemical entities for sarcopenia treatment. A working group of the European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (ESCEO) proposed classifying biochemical markers into 2 series: biochemical markers evaluating musculoskeletal status and biochemical markers evaluating causal factors. For series 1, the group agreed on 4 biochemical markers that should be assessed in Phase II or Phase III trials (i.e., Myostatin-Follistatin, Brain Derived Neurotrophic Factor, N-terminal Type III Procollagen and Serum Creatinine to Serum Cystatin C Ratio – or the Sarcopenia Index). For series 2, the group agreed on 6 biochemical markers that should be assessed in Phase II trials (i.e., the hormones insulin-like growth factor-1 (IGF-I), dehydroepiandrosterone sulphate, and cortisol, and the inflammatory markers C-reactive protein (CRP), interleukin-6 and tumor necrosis factor-α), and 2 in Phase III trials (i.e., IGF-I and CRP). The group also proposed optional biochemical markers that may provide insights into the mode of action of pharmacological therapies. Further research and development of new methods for biochemical marker assays may lead to the evolution of these recommendations.

Published
2023
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results